


Delta-19

Covid-19 + Universal Influenza Combination Vaccine









against SARS-COV-2 and all Influenza Viruses

Development

Genes for the key immunogenic proteins of SARS-CoV-2 and influenza viruses are synthesized and engineered into the Delta NS1 vaccine vector.

Delta NS1 is based on genetically modified, safely attenuated influenza virus strains that do not replicate. Delta NS1 vaccines induce a broad and potent protective immune response from multiple arms of the immune system, including interferon, IgA and IgG antibodies, and T cells.

Production

Delta-19 is produced in a fast and efficient Vero cell production system.

Proprietary purification technology ensures a pure and potent vaccine product.

Manufacture can take as little as 7 weeks from development of the genetically engineered Delta NS1 vaccine to release of the finished vaccine product.

Application

Delta-19 is administered as a nasal spray. In the nasal passages, Delta-19 rapidly induces interferon, an immune-boosting protein, and IgA antibodies that neutralize infectious SARS-CoV-2 and influenza viruses at their point of entry.

Delta-19 also induces protective T cells and IgG antibodies that circulate to the lung and other organs and tissues throughout the body, for durable systemic immunity.